Omega-3 Study

Omega – 3 Study

Are you a breast cancer survivor who recently started taking Arimidex® (anastrozole) or Femara® (letrozole)?
 
If you are, and have all of the following, you may be eligible to participate in a breast cancer clinical trial at Ohio State’s Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute:

  • Diagnosis of breast cancer
  • On aromatase inhibitor therapy for the first time
  • Not currently taking omega-3 fatty acid (fish oil) supplements


This study may improve our understanding of whether these supplements can reduce the inflammation and swelling of the joints that may be caused by aromatase inhibitor therapy.
By participating, you will help find a better way to decrease the side effects of aromatase therapy for you and for future breast cancer survivors.

You will receive six months of either omega-3 fish oil or placebo natural oils, at no cost to you.

This is a single-institution trial funded by the Cancer and Leukemia Group B/Alliance group. Maryam Lustberg, MD, is The Ohio State University site principal investigator.
 

For more information about this study or to see if you qualify, please contact Dr. Lustberg at Maryam.Lustberg@osumc.edu.
 

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu